David Espinoza

1.2k total citations
47 papers, 533 citations indexed

About

David Espinoza is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, David Espinoza has authored 47 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 11 papers in Cancer Research. Recurrent topics in David Espinoza's work include Cancer Genomics and Diagnostics (7 papers), Skin Protection and Aging (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). David Espinoza is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Skin Protection and Aging (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). David Espinoza collaborates with scholars based in Australia, New Zealand and United States. David Espinoza's co-authors include John Simes, Lisa Askie, Richard Hallinan, Anne Ε. Cust, Wendy Hague, Paul Haber, Anna Lene Seidler, Stefan Blankenberg, David Sullivan and Paul J. Nestel and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

David Espinoza

41 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Espinoza Australia 13 108 95 81 69 69 47 533
Nathalie C. Støer Norway 14 133 1.2× 152 1.6× 69 0.9× 63 0.9× 81 1.2× 48 597
Jia‐Shu Chen United States 18 83 0.8× 70 0.7× 85 1.0× 110 1.6× 61 0.9× 72 840
Sixia Chen United States 16 56 0.5× 54 0.6× 121 1.5× 67 1.0× 83 1.2× 61 622
Eleanor L. Watts United Kingdom 14 68 0.6× 88 0.9× 42 0.5× 31 0.4× 55 0.8× 28 430
Mathieu Coudert France 15 39 0.4× 112 1.2× 68 0.8× 90 1.3× 105 1.5× 39 823
Christine Garcia United States 16 74 0.7× 141 1.5× 40 0.5× 40 0.6× 61 0.9× 71 668
Brittany Irvine Canada 8 62 0.6× 88 0.9× 43 0.5× 43 0.6× 45 0.7× 12 693
Lauren Erdman Canada 18 100 0.9× 39 0.4× 96 1.2× 103 1.5× 116 1.7× 67 810
Dejana Braithwaite United States 14 103 1.0× 288 3.0× 50 0.6× 47 0.7× 148 2.1× 63 741

Countries citing papers authored by David Espinoza

Since Specialization
Citations

This map shows the geographic impact of David Espinoza's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Espinoza with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Espinoza more than expected).

Fields of papers citing papers by David Espinoza

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Espinoza. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Espinoza. The network helps show where David Espinoza may publish in the future.

Co-authorship network of co-authors of David Espinoza

This figure shows the co-authorship network connecting the top 25 collaborators of David Espinoza. A scholar is included among the top collaborators of David Espinoza based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Espinoza. David Espinoza is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Yip, Desmond, John Zalcberg, Jean‐Yves Blay, et al.. (2025). Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial. British Journal of Cancer. 132(10). 897–904. 1 indexed citations
3.
Smit, Amelia K., Andrea L. Smith, David Espinoza, et al.. (2024). Adherence to melanoma screening and surveillance skin check schedules tailored to personal risk. International Journal of Cancer. 155(11). 2058–2067.
4.
Turner, Robin, et al.. (2024). Addressing missing outcome data in randomised controlled trials: A methodological scoping review. Contemporary Clinical Trials. 143. 107602–107602. 3 indexed citations
5.
Campbell, Ian, Neil Wetzig, Owen Ung, et al.. (2023). 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. The Breast. 70. 70–75. 3 indexed citations
6.
Thavaneswaran, Subotheni, Maya Kansara, Frank Cheau‐Feng Lin, et al.. (2023). A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. British Journal of Cancer. 129(3). 475–485. 7 indexed citations
7.
Smit, Amelia K., David Espinoza, Georgina Fenton, et al.. (2022). Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study. Journal of Personalized Medicine. 12(10). 1581–1581. 1 indexed citations
8.
Mercado, Gabriela, et al.. (2022). Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis. Journal of Personalized Medicine. 12(10). 1704–1704. 1 indexed citations
9.
Sankaranarayanan, Anoop, et al.. (2021). Serum lipids and suicidal risk among patients with schizophrenia spectrum disorders: Systematic review and meta‐analysis. Acta Psychiatrica Scandinavica. 144(2). 125–152. 9 indexed citations
10.
Smit, Amelia K., David Espinoza, Mary‐Anne Young, et al.. (2021). Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: A cross‐sectional survey of health professionals. Clinical Genetics. 100(4). 430–439. 24 indexed citations
11.
12.
13.
Espinoza, David, Craig Sinclair, Yoon‐Jung Kang, et al.. (2020). Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiology. 70. 101874–101874. 15 indexed citations
14.
15.
Cust, Anne Ε., Georgina Fenton, Amelia K. Smit, et al.. (2018). Validation of Questionnaire and Diary Measures of Time Outdoors Against an Objective Measure of Personal Ultraviolet Radiation Exposure. Photochemistry and Photobiology. 94(4). 815–820. 11 indexed citations
16.
Field, Kathryn, Madeleine King, John Simes, et al.. (2017). Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology. 133(3). 623–631. 10 indexed citations
17.
Haber, Paul, et al.. (2017). Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment. Drug and Alcohol Dependence. 181. 132–139. 27 indexed citations
18.
Smit, Amelia K., David Espinoza, Ainsley J. Newson, et al.. (2016). A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public. Cancer Epidemiology Biomarkers & Prevention. 26(2). 212–221. 34 indexed citations
19.
20.
Barros, L. Felipe, Alejandro San Martín, Tamara Sotelo-Hitschfeld, et al.. (2013). Small is fast: astrocytic glucose and lactate metabolism at cellular resolution. Frontiers in Cellular Neuroscience. 7. 27–27. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nathalie C. Støer Breakdown of academic impact, for papers by Jia‐Shu Chen Breakdown of academic impact, for papers by Sixia Chen Breakdown of academic impact, for papers by Eleanor L. Watts Breakdown of academic impact, for papers by Mathieu Coudert Breakdown of academic impact, for papers by Christine Garcia Breakdown of academic impact, for papers by Brittany Irvine Breakdown of academic impact, for papers by Lauren Erdman Breakdown of academic impact, for papers by Dejana Braithwaite
Rankless by CCL
2026